A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2017
At a glance
- Drugs CMV-pp65-vaccine-PepVax (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Jun 2015 Planned primary completion date changed from 1 Aug 2019 to 1 May 2019 as reported by ClinicalTrials.gov.
- 01 Jun 2015 Planned number of patients changed from 115 to 96 as reported by ClinicalTrials.gov.